Poolbeg Pharma – a company focused on developing infectious disease therapies – has announced data from its bacterial lipopolysaccharide (LPS) human challenge trial for POLB 001.
The treatment is a viral strain agnostic, small molecule immunomodulator which is being developed to address meet medical needs emerging from severe influenza and other acute inflammatory conditions. Indeed, POLB 001 selectively inhibits overwhelming inflammation in viral infections, while leaving necessary immune functions intact to fight the infection.
The study was completed by a group of 36 healthy volunteers between the ages of 18 and 55. Those treated with POLB 001 exhibited a significant reduction in multiple markers of systemic and localised inflammation when compared with the placebo.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.